- Treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.
- Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two months of planned chemotherapy.
- Limitations of Use:
- Has not been shown to improve quality of life, fatigue, or patient well-being.
- It is not indicated for use:
- In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy.
- In patients with cancer receiving myelosuppressive chemotherapy when the outcome is cure.
- As a substitute for red blood cells (RBC) transfusions in patients who require immediate correction of anemia.
Coverage of drugs is first determined by the member’s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document.